Johnson & Johnson’s Scodari Announces Retirement As Firm Reorganizes
This article was originally published in The Pink Sheet Daily
Executive Summary
Christine Poon will assume direct responsibility for the firm’s pharmaceutical and biologics business.
You may also be interested in...
J&J Restructuring Organizes Pharma Division Into Three Businesses
Three therapeutic-based business units will bring together commercial, R&D and operational organizations, effective June 1.
J&J’s Poon Joins Management Triumvirate With Vice Chairman Appointment
Worldwide Chairman-Medicines & Nutritionals Christine Poon joins the Office of the Chairman, which includes CEO Weldon and CFO Darretta. Poon retains management responsibility for the pharmaceutical business.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee